Fulphila: payments to doctors
Payments that named Fulphila as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $81K
- Providers
- 1,038
- Transactions
- 1,589
- Average per transaction
- $51
The per-transaction average — $51 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,038 providers the average total is $78, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Mylan Institutional Inc. | $57,973 | 71.2% |
| Mylan Inc. | $15,814 | 19.4% |
| Biocon Biologics Inc | $7,501 | 9.2% |
| Mylan Pharmaceuticals Inc. | $90 | 0.1% |